4D Molecular Therapeutics LLC is planning an IPO of its common shares on the Nasdaq Global Market.
The Emeryville, Calif.-based company, led by CEO and co-founder David Kirn, researches and develops gene therapy products. 4D Molecular's product candidates include a treatment for Fabry disease, plus two products for ophthalmology.
The company plans to list its shares under the ticker symbol DDDD.
Viking Global Opportunities Illiquid Investments Sub-Master LP, along with co-founders Kirn and David Schaffer, each own a 16% stake, while Pfizer Ventures (US) LLC, the venture capital arm of Pfizer Inc., owns an 11.8% stake in the company.
Net proceeds from the IPO will go toward funding for ongoing and planned preclinical and clinical development of the company's product candidates. Proceeds will also be used to expand the company's pipeline, for working capital and general corporate purposes.
All of the company's programs are in preclinical stage of development.
Goldman Sachs & Co. LLC and Evercore Group LLC are the representatives of IPO's underwriters. William Blair & Co. LLC and Chardan Capital Markets LLC are also underwriters for the offering.
